List of Zejula drug patents
Zejula is owned by Glaxosmithkline.
Zejula contains Niraparib Tosylate.
Zejula has a total of 6 drug patents out of which 0 drug patents have expired.
Zejula was authorised for market use on 27 March, 2017.
Zejula is available in capsule;oral dosage forms.
Zejula can be used as a method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status.
Drug patent challenges can be filed against Zejula from March, 2021.
The generics of Zejula are possible to be released after 27 March, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8436185 | GLAXOSMITHKLINE | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(6 years from now) | |
| US8071623 | GLAXOSMITHKLINE | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071579 | GLAXOSMITHKLINE | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8143241 | GLAXOSMITHKLINE | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8859562 | GLAXOSMITHKLINE | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(8 years from now) | |
| US11091459 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 29, 2027 |
| New Chemical Entity Exclusivity (NCE) | Mar 27, 2022 |
| New Indication (I) | Apr 29, 2023 |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 27 March, 2017
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic